These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 29602229)

  • 1. Prospective evaluation of hematocrit in gender-affirming hormone treatment: results from European Network for the Investigation of Gender Incongruence.
    Defreyne J; Vantomme B; Van Caenegem E; Wierckx K; De Blok CJM; Klaver M; Nota NM; Van Dijk D; Wiepjes CM; Den Heijer M; T'Sjoen G
    Andrology; 2018 May; 6(3):446-454. PubMed ID: 29602229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence.
    Wierckx K; Van Caenegem E; Schreiner T; Haraldsen I; Fisher AD; Toye K; Kaufman JM; T'Sjoen G
    J Sex Med; 2014 Aug; 11(8):1999-2011. PubMed ID: 24828032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient Elevated Serum Prolactin in Trans Women Is Caused by Cyproterone Acetate Treatment.
    Defreyne J; Nota N; Pereira C; Schreiner T; Fisher AD; den Heijer M; T'Sjoen G
    LGBT Health; 2017 Oct; 4(5):328-336. PubMed ID: 28880825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No correlation between serum testosterone levels and state-level anger intensity in transgender people: Results from the European Network for the Investigation of Gender Incongruence.
    Defreyne J; Kreukels B; T'Sjoen G; Staphorsius A; Den Heijer M; Heylens G; Elaut E
    Horm Behav; 2019 Apr; 110():29-39. PubMed ID: 30822410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of gender affirming hormone treatment in transgender individuals - a retrospective cohort study.
    Muir CA; Guttman-Jones M; Man EJ
    Endocrine; 2024 Jul; 85(1):370-379. PubMed ID: 38386168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythrocytosis in a Large Cohort of Trans Men Using Testosterone: A Long-Term Follow-Up Study on Prevalence, Determinants, and Exposure Years.
    Madsen MC; van Dijk D; Wiepjes CM; Conemans EB; Thijs A; den Heijer M
    J Clin Endocrinol Metab; 2021 May; 106(6):1710-1717. PubMed ID: 33599731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of testosterone formulations on hematocrit in transgender individuals: A systematic review.
    Okano SHP; Braga GC; Cantelli DAL; Filho LASP; Brito LGO; Lara LADS
    Andrology; 2024 Jul; ():. PubMed ID: 39011565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterisation of testicular function and spermatogenesis in transgender women.
    Vereecke G; Defreyne J; Van Saen D; Collet S; Van Dorpe J; T'Sjoen G; Goossens E
    Hum Reprod; 2021 Jan; 36(1):5-15. PubMed ID: 33257947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lower Serum Estradiol Levels in Assigned Female at Birth Transgender People with Initiation of Testosterone Therapy: Results from the European Network for the Investigation of Gender Incongruence.
    Defreyne J; Aers XP; Collet SM; Wiepjes CM; Fisher AD; Schreiner T; Den Heijer M; Kaufman JM; T'Sjoen GGR
    LGBT Health; 2020; 7(2):71-81. PubMed ID: 32049583
    [No Abstract]   [Full Text] [Related]  

  • 10. Hormone Concentrations in Transgender Women Who Self-Prescribe Gender Affirming Hormone Therapy: A Retrospective Study.
    Salakphet T; Mattawanon N; Manojai N; Muangmool T; Tangpricha V
    J Sex Med; 2022 May; 19(5):864-871. PubMed ID: 35379590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of Sexual Dysfunctions in Transgender Persons: Results from the ENIGI Follow-Up Study.
    Kerckhof ME; Kreukels BPC; Nieder TO; Becker-Hébly I; van de Grift TC; Staphorsius AS; Köhler A; Heylens G; Elaut E
    J Sex Med; 2019 Dec; 16(12):2018-2029. PubMed ID: 31668732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sexual Desire Changes in Transgender Individuals Upon Initiation of Hormone Treatment: Results From the Longitudinal European Network for the Investigation of Gender Incongruence.
    Defreyne J; Elaut E; Kreukels B; Fisher AD; Castellini G; Staphorsius A; Den Heijer M; Heylens G; T'Sjoen G
    J Sex Med; 2020 Apr; 17(4):812-825. PubMed ID: 32008926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of transdermal gender-affirming hormone therapy on markers of inflammation and hemostasis.
    Schutte MH; Kleemann R; Nota NM; Wiepjes CM; Snabel JM; T'Sjoen G; Thijs A; den Heijer M
    PLoS One; 2022; 17(3):e0261312. PubMed ID: 35290388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward a Lowest Effective Dose of Cyproterone Acetate in Trans Women: Results From the ENIGI Study.
    Kuijpers SME; Wiepjes CM; Conemans EB; Fisher AD; T'Sjoen G; den Heijer M
    J Clin Endocrinol Metab; 2021 Sep; 106(10):e3936-e3945. PubMed ID: 34125226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender-affirming hormone therapy for transgender and gender-diverse adults in Australia.
    Nolan BJ; Cheung AS
    Intern Med J; 2024 Sep; 54(9):1450-1457. PubMed ID: 39056542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consecutive Cyproterone Acetate and Estradiol Treatment in Late-Pubertal Transgender Female Adolescents.
    Tack LJW; Heyse R; Craen M; Dhondt K; Bossche HV; Laridaen J; Cools M
    J Sex Med; 2017 May; 14(5):747-757. PubMed ID: 28499525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective Evaluation of Self-Reported Aggression in Transgender Persons.
    Defreyne J; T'Sjoen G; Bouman WP; Brewin N; Arcelus J
    J Sex Med; 2018 May; 15(5):768-776. PubMed ID: 29699761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SERUM HORMONE CONCENTRATIONS IN TRANSGENDER INDIVIDUALS RECEIVING GENDER-AFFIRMING HORMONE THERAPY: A LONGITUDINAL RETROSPECTIVE COHORT STUDY.
    Chantrapanichkul P; Stevenson MO; Suppakitjanusant P; Goodman M; Tangpricha V
    Endocr Pract; 2021 Jan; 27(1):27-33. PubMed ID: 33471729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiometabolic Effects of Testosterone in Transmen and Estrogen Plus Cyproterone Acetate in Transwomen.
    van Velzen DM; Paldino A; Klaver M; Nota NM; Defreyne J; Hovingh GK; Thijs A; Simsek S; T'Sjoen G; den Heijer M
    J Clin Endocrinol Metab; 2019 Jun; 104(6):1937-1947. PubMed ID: 30602016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A European Network for the Investigation of Gender Incongruence: Endocrine Part.
    Dekker MJ; Wierckx K; Van Caenegem E; Klaver M; Kreukels BP; Elaut E; Fisher AD; van Trotsenburg MA; Schreiner T; den Heijer M; T'Sjoen G
    J Sex Med; 2016 Jun; 13(6):994-9. PubMed ID: 27162190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.